---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-009137"
form_type: "8-K"
ticker: "TNGX"
cik: "0001819133"
company_name: "Tango Therapeutics, Inc."
filed_at: "2022-05-11T23:59:59+00:00"
generated_at: "2026-06-25T21:10:04.088947+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Tango Therapeutics Q1 net loss $25.2M; cash $449.9M; TNG908 trial open

## Summary
- Net loss $25.2M ($0.29/share) vs $12.1M loss in Q1 2021; R&D expense $24.3M (+62% YoY).
- Cash, cash equivalents & marketable securities $449.9M; expected to fund operations into H2 2024.
- TNG908 Phase 1/2 trial open for MTAP-deleted solid tumors; FDA Fast Track Designation granted.
- Declared TNG462 (next-gen PRMT5 inhibitor) and TNG260 (STK11-loss inhibitor) as development candidates.
- Collaboration revenue $5.8M, down from $6.4M, due to lower Gilead research costs.

## SEC filing metadata
- accession: 0000950170-22-009137
- form_type: 8-K
- ticker: TNGX
- cik: 0001819133
- company_name: Tango Therapeutics, Inc.
- filed_at: 2022-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/0000950170-22-009137-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1819133/000095017022009137/tngx-20220511.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-009137
- JSON: https://secwatch.observer/filing/0000950170-22-009137.json
- Plain text: https://secwatch.observer/filing/0000950170-22-009137.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.